GenSight Biologics s’introduit sur Euronext : la première société de thérapie génique cotée en Europe

Back

€40 million raised; market capitalisation €149 million

Paris – 13 July 2016–  EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs), today welcomed GenSight Biologics, a biopharmaceutical specialist in gene therapy,  for its first day of trading on compartment C of Euronext’s regulated market in Paris.

Founded in 2012, GenSight Biologics is an innovative young company dedicated to discovering and developing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system. Focusing initially on patients suffering from severe retinal diseases, GenSight Biologics’s current drug candidates are designed to offer patients sustainable functional visual recovery. The company’s stock market debut makes it the first listed gene therapy company in Europe.

GenSight Biologics (ticker code: SIGHT) was listed through the admission to trading on 13 July 2016 of 18,609,122 common shares, including 5,000,000 shares issued as part of a Global Offering[1], before the exercise of the over-allotment option.

GenSight Biologics’ admission and issuing price was set at €8 per share. Market capitalisation on the day of listing was €149 million. Listing raised a total of €40 million.

 “We are delighted to announce GenSight Biologics’s successful listing on Euronext Paris—a key stage in our company’s growth,” said Bernard Gilly, founder and CEO of GenSight Biologics . “It puts us on track for greater international recognition and continued development of our drug candidates for the treatment of serious neurodegenerative retinal diseases. This success is all the more satisfying in that, despite today’s difficult market environment, we have strengthened our ties with leading institutional investors in the United States and in Europe. I would like to take this opportunity to extend warm thanks to all of our shareholders—old and new, partners and employees—for their support and contribution to our successful listing.”



[1]TheGlobal Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection in order to offer patients a sustainable functional visual recovery

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.